TERMINATED

SMILE: Clinical Trial to Evaluate Mindfulness as Intervention for Racial and Ethnic Populations During COVID-19

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to evaluate the SMILE app, a Digital Health Platform (DHP), that will deliver a mindfulness intervention, designed to mitigate COVID-19 related stress. Additionally, the SMILE app will remotely collect self-reported psychological and physiological metrics of mental health and autonomic regulation. Study participants are adults who self-identify as African American, Black and/or Latino, and who have clinically significant levels of anxiety. The study aims are: * Aim 1: Establish the effectiveness and durability of an 8-week Mindfulness DHP intervention. The investigators will focus on two constructs important to mental health and hypothesize that: A) Anxiety, self-report stress and quality-of-life measures will significantly improve when comparing: A.1) Pre-to-post intervention, and; A.2) Control vs. intervention groups over 8 weeks and at 1-month follow-up. B) Arousal, autonomic indices of HRV (reflecting parasympathetic activation) will significantly improve, when comparing: B.1) Pre-to-post intervention, and; B.2) Control vs. intervention groups over 8 weeks and at 1-month follow-up. * Aim 2: Establish the sustainability of two Mindfulness DHP interventions utilizing retention, usage (frequency), and participant satisfaction. * Aim 3: Examine associations between COVID-19 related stress, mental health outcomes, and HRV. Examine the extent to which COVID-19 related stress and mental health symptoms are linked to HRV at baseline and how that relationship changes over time. Participants will be assigned to 1 of 3 arms of the study: MTIA intervention, MAPP intervention, or wait-list control. All participants will be mailed a device with the SMILE app installed, and the equipment for recording cardiac data in the home. All participants will complete the baseline psychometrics measures and physiological stress test using the instructions provided on the SMILE app. Those assigned to the MTIA or MAPP intervention groups will then participate in their assigned intervention over the subsequent 8 weeks. During these 8 weeks, psychometric and physiological data will be completed biweekly for all participants. 3 months following the initial baseline, all participants will complete a final psychometric/physiological evaluation.

Official Title

Digital Health Platform (DHP) to Deliver Mindfulness as a Stress Management Intervention Leveraging Electronic (SMILE) Health Records for Racial and Ethnic Populations During the COVID-19 Pandemic: Clinical Trial

Quick Facts

Study Start:2024-05-13
Study Completion:2025-05-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:TERMINATED

Study ID

NCT06242080

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * self-identify as African American, Black, Hispanic and/or Latino
  2. * demonstrate symptoms of anxiety, as determined based on the GAD-7 screening measure (score between 8-14)
  1. * Current, or history of, heart disease
  2. * History of stroke or dementia
  3. * Diagnosis of movement disorders, such as Parkinson's Disease, or paralysis
  4. * Diagnosis of genetic disorders, such as Down Syndrome or Fragile-X syndrome
  5. * Diagnosis of autism
  6. * Diagnosis of schizophrenia, psychosis, dissociative disorder, mania/bipolar disorder, major depression or a personality disorder
  7. * History of serious mental or behavioral health problems requiring a hospital or treatment center stay within the past 12 months
  8. * Taking cardiac medications (other than blood pressure medications)
  9. * Taking seizure medications
  10. * Currently taking opioids medications or supplements
  11. * Practice of formal mindfulness for more than 15 minutes/day for 4 or more days/week over the past 6 months
  12. * GAD score \<8 or \>14

Contacts and Locations

Principal Investigator

Susan Gaylord, PhD
PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill
Maria Davila, PhD
PRINCIPAL_INVESTIGATOR
Research Triangle Institute (RTI)
Keri J Heilman, PhD
PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill

Study Locations (Sites)

University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7160
United States

Collaborators and Investigators

Sponsor: University of North Carolina, Chapel Hill

  • Susan Gaylord, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill
  • Maria Davila, PhD, PRINCIPAL_INVESTIGATOR, Research Triangle Institute (RTI)
  • Keri J Heilman, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-13
Study Completion Date2025-05-27

Study Record Updates

Study Start Date2024-05-13
Study Completion Date2025-05-27

Terms related to this study

Keywords Provided by Researchers

  • Digital Health Platform
  • Heart Rate Variability
  • Mindfulness
  • Cultural/ethnic health disparities

Additional Relevant MeSH Terms

  • Anxiety
  • COVID-19 Pandemic